Matthew J. During

Dr. During is a MIT, Harvard and Yale-trained MD/PhD neuroscientist. He served nine years on faculty of Yale University as Professor of Neurosurgery. Subsequently, Dr. During served as a Professor at Cornell and Ohio State Universities for ten years. Since 2011, he has served as a visiting Professor of Translational Neuroscience at the University of Oxford. Dr. During pioneered the use of viral vectors for neurological disorders, and was the first to carry out gene transfer into the brain of a pediatric patient. He was the Principal Investigator and the FDA sponsor for two pioneering gene therapy studies, including the first and only successful Phase 2 trial of a biological therapy for Parkinson’s disease. He has published over 225 articles, with many in the world’s most prestigious journals including Nature, Science, Cell, Nature Medicine, Nature Genetics, the Lancet and Science Translational Medicine. He is the inventor on over 50 patents and patent applications. In addition, Dr. During has won many awards including the American Epilepsy Society Young Investigator of the Year, Roche Translational Neuroscience Award, Johnson and Johnson Focused Giving Award, BMS Neuroscience Award, and Nancy Sirrett and Keith Harrison Awards. He is a Fellow of the American College of Physicians, the Australasian College of Physicians, and a Fellow of the American Association for the Advancement of Science. He previously co-founded Merlin Pharmaceuticals, Neurologix and NightstaRx.